Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
88 hedge funds and large institutions have $416M invested in Generation Bio in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 30 reducing their positions, and 14 closing their positions.
100% more call options, than puts
Call options by funds: $2K | Put options by funds: $1K
7% more capital invested
Capital invested by funds: $390M → $416M (+$25.7M)
3% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 30
0.25% more ownership
Funds ownership: 9.66% → 9.91% (+0.25%)
0% more funds holding
Funds holding: 88 → 88 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$15.1M |
| 2 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$3.61M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$3.33M |
| 4 |
Goldman Sachs
New York
|
+$777K |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$761K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.31M |
| 2 |
Millennium Management
New York
|
-$3.81M |
| 3 |
Bank of New York Mellon
New York
|
-$2.69M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$1.1M |
| 5 |
Renaissance Technologies
New York
|
-$906K |
GBIO Hedge Fund Activity: Q1 2022 in Review
88 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q1 2022, worth a combined $416M — up 6.6% from $390M a quarter earlier.
Fund positioning in GBIO was balanced in Q1 2022: 14 funds opened new positions, 14 closed out, 31 added to existing stakes and 30 trimmed.
The largest buyer was BVF Inc, adding an estimated $15.1M. The largest seller was State Street, cutting an estimated $6.31M.
- 88 institutional investors held Generation Bio (GBIO) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $416M of Generation Bio stock for Q1 2022, up 6.6% quarter-over-quarter.
- 14 funds opened new Generation Bio positions in Q1 2022 and 14 closed out, a net change of 0 holders.
- The largest Generation Bio buyer in Q1 2022 was BVF Inc, an estimated $15.1M added.
- The largest Generation Bio seller in Q1 2022 was State Street, an estimated $6.31M sold.
Based on aggregated 13F filings for Q1 2022.